Руководство

POSITION

Sirius University Academic Council Chairman, Science and Technology Council Member, Translational Medicine Research Center Director, Medical Biotechnology Research Director

EDUCATION AND ACADEMIC DEGREES

PhD in Molecular Immunology (Utrecht University, the Netherlands)

WORK EXPERIENCE

From 2005 to 2019, he worked at BIOCAD, a Russian high-tech pharmaceutical company, first as Medical Director and then as Vice President of Research and Development, responsible for development of biosimilars and original monoclonal antibody-based drugs. Ivanov led research team had developed complex biological drugs creation technology starting from gene generation to finished dosage form. Biosimilar monoclonal antibodies, including rituximab, trastuzumab, bevacizumab, and adalimumab hold leading market positions in Russia and several other countries. Netakimab (anti-IL17) and prolgolimab (anti-PD1) were the first original monoclonal antibody drugs registered in Russia. Roman also oversaw the start of gene therapy drug development.